CN111448193B - Srpk1抑制剂 - Google Patents
Srpk1抑制剂 Download PDFInfo
- Publication number
- CN111448193B CN111448193B CN201880075104.5A CN201880075104A CN111448193B CN 111448193 B CN111448193 B CN 111448193B CN 201880075104 A CN201880075104 A CN 201880075104A CN 111448193 B CN111448193 B CN 111448193B
- Authority
- CN
- China
- Prior art keywords
- methyl
- compound
- phenyl
- cyclopropyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1715637.3A GB201715637D0 (en) | 2017-09-27 | 2017-09-27 | SRPK1 Inhibitors |
| GB1715637.3 | 2017-09-27 | ||
| GB1810765.6 | 2018-06-29 | ||
| GBGB1810765.6A GB201810765D0 (en) | 2018-06-29 | 2018-06-29 | SRPK1 inhibitors |
| PCT/GB2018/052735 WO2019063996A1 (en) | 2017-09-27 | 2018-09-26 | INHIBITORS OF SRPK1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111448193A CN111448193A (zh) | 2020-07-24 |
| CN111448193B true CN111448193B (zh) | 2023-12-22 |
Family
ID=63722692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880075104.5A Active CN111448193B (zh) | 2017-09-27 | 2018-09-26 | Srpk1抑制剂 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11420969B2 (enExample) |
| EP (1) | EP3687990A1 (enExample) |
| JP (1) | JP7261793B2 (enExample) |
| CN (1) | CN111448193B (enExample) |
| AU (1) | AU2018341084B2 (enExample) |
| CA (1) | CA3077749A1 (enExample) |
| WO (1) | WO2019063996A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3821947A1 (en) * | 2019-11-13 | 2021-05-19 | Libra Therapeutics, Inc. | Heterocyclic trpml1 agonists |
| US12698266B2 (en) | 2019-12-19 | 2026-08-04 | Casma Therapeutics, Inc. | TRPML modulators |
| GB202010829D0 (en) | 2020-07-14 | 2020-08-26 | Exonate Ltd | Compounds for treatment of neovascular diseases |
| US20240221945A1 (en) * | 2023-01-03 | 2024-07-04 | Industry-Academic Cooperation Foundation, Yonsei University | Server and method for predicting incidence of moyamoya disease through learning of fundus image |
| CN120917015A (zh) * | 2023-01-20 | 2025-11-07 | 元启(苏州)生物制药有限公司 | Srpk1抑制剂和使用方法 |
| WO2025243082A2 (en) * | 2024-05-24 | 2025-11-27 | The Chinese University Of Hong Kong | Covalent protein-protein interaction inhibitor against srpks |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101837125A (zh) * | 2003-12-26 | 2010-09-22 | 萩原正敏 | Sr蛋白质的磷酸化控制方法以及以包含sr蛋白质活性控制剂的试剂为有效成分的抗病毒剂 |
| WO2014060763A1 (en) * | 2012-10-17 | 2014-04-24 | The University Of Bristol | Compounds useful for treating ocular neovasculan |
| WO2015159103A1 (en) * | 2014-04-17 | 2015-10-22 | The University Of Nottingham | Piperazine derivatives for treating disorders |
| WO2017064512A1 (en) * | 2015-10-16 | 2017-04-20 | Exonate Limited | Compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002317333C1 (en) | 2001-08-01 | 2009-06-25 | University Of Bristol | VEGF isoform |
| AU2003249741A1 (en) * | 2002-07-03 | 2004-01-23 | Hartmut M. Hanauske-Abel | Methods of inhibiting 4-hydroxyphenylpyruvate dioxygenase in a living system |
| MXPA05011503A (es) * | 2003-04-25 | 2006-05-31 | Johnson & Johnson | Inhibidores de la c-fms cinasa. |
| WO2008076918A2 (en) * | 2006-12-15 | 2008-06-26 | University Of Maryland, Baltimore | Anti-cancer agents and androgen inhibition activity compound |
| US20140249135A1 (en) | 2007-03-01 | 2014-09-04 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| CN101679266B (zh) | 2007-03-01 | 2015-05-06 | 诺华股份有限公司 | Pim激酶抑制剂及其应用方法 |
| GB0704678D0 (en) | 2007-03-09 | 2007-04-18 | Univ Bristol | Pro- and anti-angiogenic treatments |
| WO2009020198A1 (ja) | 2007-08-03 | 2009-02-12 | Kinopharma, Inc. | 抗ｄｎａウイルス作用を有するアニリン誘導体 |
| GB0803912D0 (en) | 2008-02-29 | 2008-05-07 | Univ Bristol | Novel Uses of VEGFxxxb |
| EP2358382A2 (en) | 2008-11-22 | 2011-08-24 | The University of Bristol | NOVEL USES OF VEGFxxxB |
| WO2011036429A1 (en) | 2009-09-25 | 2011-03-31 | The University Of Bristol | Detection of risk of pre-eclampsia |
| GB201009173D0 (en) | 2010-05-28 | 2010-07-14 | Univ Bristol | Treatment of pain |
| US9321740B2 (en) * | 2011-01-26 | 2016-04-26 | Zafgen, Inc. | Tetrazole compounds and methods of making and using same |
| EP3256461B1 (en) * | 2015-02-13 | 2023-09-13 | Azienda Ospedaliera Universitaria Senese | Urea and sulfonamide derivatives as human helicase ddx3 inhibitors useful in the treatment of viral diseases |
| WO2020097408A1 (en) * | 2018-11-09 | 2020-05-14 | Nimbus Artemis, Inc. | Acly inhibitors and uses thereof |
-
2018
- 2018-09-26 CA CA3077749A patent/CA3077749A1/en active Pending
- 2018-09-26 US US16/651,182 patent/US11420969B2/en active Active
- 2018-09-26 CN CN201880075104.5A patent/CN111448193B/zh active Active
- 2018-09-26 EP EP18782140.0A patent/EP3687990A1/en active Pending
- 2018-09-26 WO PCT/GB2018/052735 patent/WO2019063996A1/en not_active Ceased
- 2018-09-26 JP JP2020517549A patent/JP7261793B2/ja active Active
- 2018-09-26 AU AU2018341084A patent/AU2018341084B2/en active Active
-
2022
- 2022-08-04 US US17/880,925 patent/US12325704B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101837125A (zh) * | 2003-12-26 | 2010-09-22 | 萩原正敏 | Sr蛋白质的磷酸化控制方法以及以包含sr蛋白质活性控制剂的试剂为有效成分的抗病毒剂 |
| WO2014060763A1 (en) * | 2012-10-17 | 2014-04-24 | The University Of Bristol | Compounds useful for treating ocular neovasculan |
| WO2015159103A1 (en) * | 2014-04-17 | 2015-10-22 | The University Of Nottingham | Piperazine derivatives for treating disorders |
| WO2017064512A1 (en) * | 2015-10-16 | 2017-04-20 | Exonate Limited | Compounds |
Non-Patent Citations (3)
| Title |
|---|
| Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease;Jennifer,等;《ACS Chemical Biology》;20170130;第12卷(第3期);825-832 * |
| STN-REGISTRY.REGISTRY-RN.《REGISTRY-数据库记录》.2015, * |
| Topical Antiangiogenic SRPK1 Inhibitors Reduce Choroidal Neovascularization in Rodent Models of Exudative AMD;Gammons,等;《INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE》;20130930;第54卷(第9期);6052-6062 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200270249A1 (en) | 2020-08-27 |
| EP3687990A1 (en) | 2020-08-05 |
| JP7261793B2 (ja) | 2023-04-20 |
| AU2018341084A1 (en) | 2020-04-23 |
| US20220389015A1 (en) | 2022-12-08 |
| US12325704B2 (en) | 2025-06-10 |
| WO2019063996A1 (en) | 2019-04-04 |
| CA3077749A1 (en) | 2019-04-04 |
| CN111448193A (zh) | 2020-07-24 |
| US11420969B2 (en) | 2022-08-23 |
| JP2020535172A (ja) | 2020-12-03 |
| AU2018341084B2 (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3007462C (en) | Compounds and methods for kinase modulation, and indications therefor | |
| EP3430005B1 (en) | Compounds and methods for kinase modulation and indications therefore | |
| US10829484B2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| JP7261793B2 (ja) | Ｓｒｐｋ１阻害剤 | |
| CN108738319B (zh) | 用于抗血管生成治疗或预防的化合物 | |
| CN107001344B (zh) | 用于治疗病症的哌嗪衍生物 | |
| JP2019048833A (ja) | Ｆａｓｎを阻害するための新規化合物および組成物 | |
| WO2016164641A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| JP2021510151A (ja) | アルツハイマー病等のタウ凝集体に関連する障害の治療、緩和、または予防のための１，３，４，５−テトラヒドロ−２ｈ−ピリド（４，３−ｂ）インドール誘導体 | |
| US12297186B2 (en) | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 | |
| JP2022547294A (ja) | キナーゼ阻害剤としての３，５－ジ置換ピラゾール化合物およびその応用 | |
| JP2018203748A (ja) | 眼血管形成（ｏｃｕｌａｒ ｎｅｏｖａｓｃｕｌａｎ）を治療するのに有用な化合物 | |
| WO2006132192A1 (ja) | 新規２－キノロン誘導体 | |
| WO2018035950A1 (zh) | 作为酪氨酸蛋白激酶抑制剂的一类化合物 | |
| JP2010534231A (ja) | デュシェンヌ型筋ジストロフィーを治療するための化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |